Progression-free and overall survival for patients receiving fludarabine and cyclophosphamide (FC), and FCR as salvage therapy at MD Anderson Cancer Center. (A) Progression-free survival (PFS) for relapsed/refractory patients treated with FCR versus a historic group treated with fludarabine and cyclophosphamide (FC). (B) Overall survival (OS) for relapsed/refractory patients treated with FCR versus a historic group treated with FC.